Novartis Aktie 1200526 / CH0012005267
Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Orderbuch | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
30.08.2025 16:59:44
|
Press Release: Novartis Leqvio(R) shows -2-
information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.
References
1. Novartis. Data on file.
2. Landmesser U, Laufs U, Schatz U, et al. Design and rationale of the
VICTORION-Difference study: A phase 4 randomized, double-blind,
placebo-controlled clinical trial to assess inclisiran's early efficacy,
safety, tolerability, as well as its impact on quality of life in
individuals with hypercholesterolemia. Am Heart J. 2025;289:117-126.
doi:10.1016/j.ahj.2025.05.014
3. Leqvio. Summary of Product Characteristics. Novartis.
4. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp.
5. National Medical Products Administration. Drug approval document delivery
information. Published August 24, 2023. Accessed August 11, 2025.
https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230824155809182.html
6. Pharmaceutical and Medicinal Devices Agency Japan. New drugs approved in
FY 2023 document. Accessed August 11, 2025.
https://www.pmda.go.jp/files/000269225.pdf
7. ClinicalTrials.gov. NCT05192941. Accessed August 11, 2025.
https://clinicaltrials.gov/study/NCT05192941
8. American Heart Association. More than half of U.S. adults don't know
heart disease is leading cause of death, despite 100-year reign.
Published January 24, 2024. Accessed August 11, 2025.
https://newsroom.heart.org/news/more-than-half-of-u-s-adults-dont-know-heart-disease-is-leading-cause-of-death-despite-100-year-reign
9. World Heart Federation. World Heart Report. Published May 20, 2023.
Accessed August 11, 2025.
https://world-heart-federation.org/wp-content/uploads/World-Heart-Report-2023.pdf
10. World Health Organization. Cardiovascular diseases (CVDs). Published June
11, 2021. Accessed August 11, 2025.
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-
(cvds)
11. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke
statistics-2012 update: a report from the American Heart Association.
Circulation. 2012;125(1):e2-e220.
12. Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic
cardiovascular disease and its risk factors in Korea: a nationwide
population-based study. BMC Public Health. 2019;19(1):112.
13. Grundy SM, Stone NJ, Bailey AL, et al. 2018
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the
management of blood cholesterol: a report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines. Circulation. 2019;139:e1082-e1143.
14. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from
plaques to genes to statins. Cell. 2015;161(1):161-172.
15. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on
cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol.
2018;72(10):1141-1156.
# # #
Novartis Media Relations
E-mail: media.relations@novartis.com
Novartis Investor Relations
Central investor relations line:
+41 61 324 7944
E-mail: investor.relations@novartis.com
(END) Dow Jones Newswires
August 30, 2025 11:00 ET (15:00 GMT)
Nachrichten zu Novartis AG
12:29 |
Novartis Aktie News: Novartis gewinnt am Freitagmittag (finanzen.ch) | |
12:26 |
Börse Europa: STOXX 50 am Mittag mit Kursplus (finanzen.ch) | |
12:26 |
Börse Zürich in Grün: SLI mittags im Plus (finanzen.ch) | |
09:29 |
Novartis Aktie News: Anleger greifen bei Novartis am Freitagvormittag zu (finanzen.ch) | |
02.10.25 |
SMI-Handel aktuell: SMI liegt zum Ende des Donnerstagshandels im Plus (finanzen.ch) | |
02.10.25 |
Novartis Aktie News: Novartis macht am Donnerstagnachmittag Boden gut (finanzen.ch) | |
02.10.25 |
Gute Stimmung in Zürich: SMI präsentiert sich zum Start fester (finanzen.ch) |
Analysen zu Novartis AG
24.09.25 | Novartis Neutral | UBS AG | |
22.09.25 | Novartis Neutral | UBS AG | |
17.09.25 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
12.09.25 | Novartis Neutral | UBS AG | |
12.09.25 | Novartis Sell | Goldman Sachs Group Inc. |
Krypto-ETPs im Fokus: Regulierung, Verwahrung & Produktentwicklung | BX Swiss TV
David Kunz spricht mit Vera Claas, Geschäftsführerin von nxtAssets über die Zukunft von Krypto-ETPs. Im Fokus stehen physisch hinterlegte Bitcoin- und Ethereum-Produkte, regulatorische Rahmenbedingungen und die strategische Ausrichtung des Unternehmens. Auch geplante Produktentwicklungen und Zielgruppen kommen zur Sprache.
Themen im Video:
🔹 Die Idee hinter nxtAssets
🔹 warum physische Besicherung und Verwahrung ein echter Gamechanger für Bitcoin- und Ethereum-ETPs sind
🔹 regulatorische Vorteile im Vergleich zu internationalen Anbietern
🔹 institutionelle Investoren, Due Diligence und Vertrauen
🔹 Zukunftspläne: Baskets, neue ETPs & digitale Assets
🔹 Defi & Ethereum – das persönliche Lieblingsprojekt von Vera Claas
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Zinshoffnung: SMI fester -- DAX fällt zurück -- Asiens Börsen gehen uneinheitlich aus dem FreitagshandelDer heimische Aktienmarkt zeigt sich am Freitag von seiner freundlichen Seite. Der deutsche Aktienmarkt dreht unterdessen ins Minus. Die Börsen in Fernost schlugen am Freitag unterschiedliche Richtungen ein.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |